By VETTAPHARMA reporter – Derek Roche: Eli Lilly and Company is expanding access to its obesity medicines through the Medicare GLP-1 Bridge program, under which eligible Medicare Part D beneficiaries may be able to access Lilly obesity medicines for $50 per month.
The program is intended to improve access to obesity medicines for eligible patients and reflects Lilly’s broader focus on addressing obesity as a chronic disease and improving affordability and access to treatment.
Under the program, eligible Medicare Part D beneficiaries may be able to obtain Lilly obesity medicines at the stated monthly cost. Access is not guaranteed, and eligibility will be determined through prior authorization.
Lilly describes obesity as a condition that extends beyond body weight and emphasizes the importance of addressing its broader impact on health. The company is also working with policymakers and the healthcare system to improve access to obesity medicines.
The initiative forms part of Lilly’s broader efforts to address healthcare access alongside its work in areas including Alzheimer’s disease, cancer, diabetes, autoimmune diseases, dermatology, migraine and sleep apnea.
Lilly said its approach is focused on developing medicines while also seeking ways to make them more accessible to people who need them.
Quick FAQs
1. What Is The Announcement?
Lilly is highlighting its Medicare GLP-1 Bridge program, which may provide eligible Medicare Part D beneficiaries access to Lilly obesity medicines for $50 per month.
2. Who May Be Eligible?
Eligible Medicare Part D beneficiaries may be able to participate, subject to Lilly’s program requirements and prior authorization.
3. Is Coverage Guaranteed?
No. Lilly states that eligibility does not guarantee coverage and will be determined through prior authorization.
4. What Is The Purpose Of The Program?
The program is intended to improve access and affordability of Lilly obesity medicines for eligible Medicare beneficiaries.
5. What Other Areas Does Lilly Focus On?
Lilly’s broader therapeutic focus includes Alzheimer’s disease, cancer, diabetes, autoimmune diseases, dermatology, migraine, obesity and sleep apnea.
